New Tool for Cancer Gene Therapy: Researchers Develop FluoroDetect Assay

Strategic Insights -

Researchers from the University of Cologne have made a significant breakthrough in the field of cancer gene therapy. A new tool, the FluoroDetect assay, has been developed to assess the functionality of nucleic acid-based therapeutics, such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs). This innovative assay uses a dual fluorescence-based approach to measure the cellular distribution of NA therapeutics, providing a valuable tool for optimizing and quantifying NA delivery in NA-based therapies.

Key Takeaways:

  • The FluoroDetect assay is a sensitive dual fluorescence-based assay for testing siRNAs, ASOs, and RNA-binding compounds.
  • The assay can be adapted for use with different target sites and can be used as a quick transient model or as a lentiviral reporter for long-term experiments.
  • The assay provides a valuable tool for screening NA drug candidates and facilitating the optimization and quantification of NA delivery in NA-based therapies.
  • The researchers from the University of Cologne used the HSat3 RNA as a prime target in their proof-of-principle experiment.
  • Felix Heß, Elena Wasserburger-Zichel, Christina Grimm, and Michal R. Schweiger co-authored the research with Margarete Odenthal from the Institute of Pathology, Faculty of medicine and University Hospital Cologne.

Statistics:

  • The FluoroDetect assay was designed to be used with various forms of fluorescence microscopy, plate reading, or flow cytometry.
  • The assay can be used to measure the cellular distribution of NA therapeutics in a quick and efficient manner.
  • The HSat3 RNA was used as a prime target in the proof-of-principle experiment.
  • The FluoroDetect assay is a valuable tool for optimizing and quantifying NA delivery in NA-based therapies.

Sources:

  • NewsRx editors
  • A dual fluorescence-based reporter assay for real-time determination of siRNA- and antisense oligonucleotide-mediated knockdown. Molecular Therapy - Nucleic Acids, 2025;36(3):102631.
  • Margarete Odenthal, Institute of Pathology, Faculty of medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
  • Felix Heß, Elena Wasserburger-Zichel, Christina Grimm, and Michal R. Schweiger (co-authors)
  • Cell Press, 50 Hampshire St, Floor 5, Cambridge, MA 02139, USA. (Nature Publishing Group - www.nature.com/)